A5062778031- Lung Cancer Research Studies
- Testicular diseases and treatments
- RNA modifications and cancer
- Sarcoma Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Neuroendocrine Tumor Research Advances
- Cancer-related molecular mechanisms research
- Cancer therapeutics and mechanisms
- Lung Cancer Treatments and Mutations
- Renal and related cancers
- Ovarian cancer diagnosis and treatment
- Neuroblastoma Research and Treatments
Heinrich Heine University Düsseldorf
2023-2025
Düsseldorf University Hospital
2023-2025
University of Cologne
2020-2022
University Hospital Cologne
2020-2022
Loss of TP53 and RB1 in treatment-naïve small cell lung cancer (SCLC) suggests selective pressure to inactivate death pathways prior therapy. Yet, which these remain available SCLC is unknown. Here, through systemic analysis pathway availability SCLC, we identify non-neuroendocrine (NE) be vulnerable ferroptosis subtype-specific lipidome remodeling. While NE resistant, it acquires addiction the TRX anti-oxidant pathway. In experimental settings non-NE/NE intratumoral heterogeneity, non-NE or...
Despite the clinical efficacy of epidermal growth factor receptor (EGFR) inhibitors, a subset patients with non-small cell lung cancer displays insertion mutations in exon20 EGFR and Her2 limited treatment options. Here, we present development characterization novel covalent inhibitors LDC8201 LDC0496 based on 1H-pyrrolo[2,3-b]pyridine scaffold. They exhibited intense inhibitory potency toward as well selectivity over wild type within kinome. Complex crystal structures biochemical cellular...
In germ cell tumors (GCT), a growing teratoma during chemotherapy with decreasing tumor markers was defined as 'growing syndrome` (GTS) by Logothetis et al., in 1982. So far, its pathogenesis and specific treatment options remain elusive. We aimed at updating the GTS definition based on molecular epigenetic features well identifying circulating biomarkers. selected 50 patients for clinical characterization subsequently 12 samples were molecularly analyzed. further included 7 longitudinal of...
Abstract Background Being the standard-of-care for four decades, cisplatin-based chemotherapy is highly efficient in treating germ cell tumors (GCT). However, often refractory patients present with a remaining (resistant) yolk-sac tumor (YST(-R)) component, resulting poor prognosis due to lack of novel treatment options besides and surgery. The aim this study was identify targets YST by deciphering molecular mechanisms therapy resistance. Additionally, we screened cytotoxic efficacy...
Abstract Relapsing germ cell tumor (GCT) patients often harbor components of the aggressive subtype yolk‐sac (YST), suggesting that YST formation is an escape mechanism under therapy. Nevertheless, molecular mechanisms inducing development from its stem cell‐like precursor embryonal carcinoma (EC) are largely unexplored. We demonstrated induction transcription factor SOX17 together with stimulation WNT, TGF‐beta / Activin, and FGF signaling drives EC cells into lineage. Single RNA sequencing...
Abstract Bi-allelic loss of TP53 and RB1 in treatment-naïve small cell lung cancer (SCLC) suggests strong selective pressure to inactivate regulated death pathways prior therapy. Yet, which remain available SCLC is unknown. Here, through systemic analysis pathway availability, we identify non-neuroendocrine (NE) NE subtypes segregate by their response ferroptosis, a recently described iron-dependent type necrosis. While that extrinsic apoptosis necroptosis are incapacitated, find non-NE be...